Symptoms and quality of life in patients with brain metastases receiving whole-brain radiation therapy

2016 ◽  
Vol 24 (11) ◽  
pp. 4747-4759 ◽  
Author(s):  
Erin Wong ◽  
Liying Zhang ◽  
Leigha Rowbottom ◽  
Nicholas Chiu ◽  
Leonard Chiu ◽  
...  
2016 ◽  
Vol 20 (5) ◽  
pp. AE-02 ◽  
Author(s):  
Fatma Teke ◽  
Pakize Bucaktepe ◽  
Erkan Kıbrıslı ◽  
Melike Demir ◽  
Aslıhan Ibiloglu ◽  
...  

2020 ◽  
Vol 107 (3) ◽  
pp. 478-486
Author(s):  
Michelle M. Kim ◽  
Hemant A. Parmar ◽  
Matthew Schipper ◽  
Theresa Devasia ◽  
Madhava P. Aryal ◽  
...  

2011 ◽  
Vol 115 (1) ◽  
pp. 37-48 ◽  
Author(s):  
Stephen Rush ◽  
Robert E. Elliott ◽  
Amr Morsi ◽  
Nisha Mehta ◽  
Jeri Spriet ◽  
...  

Object In this paper, the authors' goal was to analyze the incidence, timing, and treatment of new metastases following initial treatment with 20-Gy Gamma Knife surgery (GKS) alone in patients with limited brain metastases without whole-brain radiation therapy (WBRT). Methods A retrospective analysis of 114 consecutive adults (75 women and 34 men; median age 61 years) with KPS scores of 60 or higher who received GKS for 1–3 brain metastases ≤ 2 cm was performed (median lesion volume 0.35 cm3). Five patients lacking follow-up data were excluded from analysis. After treatment, patients underwent MR imaging at 6 weeks and every 3 months thereafter. New metastases were preferentially treated with additional GKS. Indications for WBRT included development of numerous metastases, leptomeningeal disease, or diffuse surgical-site recurrence. Results The median overall survival from GKS was 13.8 months. Excluding the 3 patients who died before follow-up imaging, 12 patients (11.3%) experienced local failure at a median of 7.4 months. Fifty-three patients (50%) developed new metastases at a median of 5 months. Six (7%) of 86 instances of new lesions were symptomatic. Most patients (67%) with distant failures were successfully treated using salvage GKS alone. Whole-brain radiotherapy was indicated in 20 patients (18.3%). Thirteen patients (11.9%) died of neurological disease. Conclusions For patients with limited brain metastases and functional independence, 20-Gy GKS provides excellent disease control and high-functioning survival with minimal morbidity. New metastases developed in almost 50% of patients, but additional GKS was extremely effective in controlling disease. Using our algorithm, fewer than 20% of patients required WBRT, and only 12% died of progressive intracranial disease.


Author(s):  
L. Khan ◽  
M. Tsao ◽  
N. Pulenzas ◽  
L. Zhang ◽  
N. Thavarajah ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document